|Articles|August 27, 2015
Novo Nordisk to Start Phase III Trial for Oral Biologic
Author(s)Randi Hernandez
August 27, 2015.
Advertisement
Novo Nordisk has big plans for its diabetes franchise. Yesterday the company announced that it would begin Phase IIIa trials for oral semaglutide, a protein product that can be administered orally, rather than via injection. In the first trial of the program-which is slated to begin in 2016-doses of 3 mg, 7 mg, and 14 mg of the long-acting glucagon-like peptide-1 (GLP-1) analog will be compared with a 100-mg dose of sitagliptin, another oral diabetes medication. The other parts of the program will roll out during 2016 as well.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Evolving Relationship Between FDA and Biotech
2
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
3
The Implications of GLP-1s Replacing Oncology as the Key Value Driver
4
Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi
5